Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Considerations for the Use of JAK Inhibitors in Young Female Patients

Description

The discussion focuses on the unique considerations for prescribing JAK inhibitors to young female patients, particularly those of reproductive age. As these patients may become pregnant or wish to breastfeed, health professionals must ensure they are well-informed about potential risks. JAK inhibitors are often excluded from clinical studies involving pregnant women, leading to a lack of human data but existing animal studies indicate concerns about fetal exposure and teratogenic effects at high doses. It's crucial to counsel patients about the limited data and potential risks while recommending effective contraception. In cases where patients become pregnant while on these medications, initial data suggests that outcomes may be similar to the general population, with some instances of live births without congenital abnormalities. Notably, studies have shown no adverse interactions between JAK inhibitors and oral contraceptives, alleviating concerns about diminished efficacy. Furthermore, evidence indicates that the combined use of oral contraceptives and JAK inhibitors does not significantly increase risks for venous thromboembolic events. Overall, the presentation advocates for treating young women with JAK inhibitors with the proper counseling and monitoring, suggesting that these patients can be safely managed under appropriate guidance.

View more

Conclusions

JAK inhibitors raise unique concerns regarding their use in young females due to reproductive considerations.
Data on the use of JAK inhibitors during pregnancy and lactation is largely based on animal studies due to exclusion of pregnant individuals from clinical trials.
Animal studies indicate that some JAK inhibitors can cross the placenta and may cause teratogenic effects at high doses.
JAK inhibitors are contraindicated in pregnancy and lactation based on available data.
A waiting period of at least four weeks is recommended after the last dose of JAK inhibitors before attempting pregnancy.
Counseling on the lack of human data and potential risks is essential for patients of reproductive potential taking JAK inhibitors.
Effective contraception is strongly recommended for young women taking JAK inhibitors.
Current studies indicate no significant drug interactions between JAK inhibitors and oral contraceptive pills.
Existing data suggests that pregnancy outcomes for women exposed to JAK inhibitors during early pregnancy may not be significantly worse than background rates for spontaneous abortion and major birth defects.
Overall, treating young women with reproductive potential using JAK inhibitors is considered acceptable with proper counseling and precautions.

Nash et al. Ann Rheum Dis. 2021 Jan:80(1):71-87.
Charles-Schoeman et al. RMD Open. 2023; 9(4): e003392